Search results
Results From The WOW.Com Content Network
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services.
The PDQ NCI Cancer Terms Database is a resource of cancer-related terms, curated by a multidisciplinary panel of reviewers, that is released monthly. The NCI Drug Dictionary is a structured list of technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer.
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
Malignancy (from Latin male 'badly' and -gnus 'born') is the tendency of a medical condition to become progressively worse; the term is most familiar as a characterization of cancer.
The NCI considers the certain characteristics essential to a cancer center, and requires that applications address the institutions' resources in the areas of: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, Center Director.
Resistant cancer or refractory cancer is the cancer that ... This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer ...
Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. [1]
The use of TILs as an adoptive cell transfer therapy to treat cancer was pioneered by Dr. Steven Rosenberg and colleagues at the Surgery Branch of the National Cancer Institute (NCI). [17] Rosenberg and colleagues have conducted clinical trials for more than two decades using TIL adoptive cell therapy for melanoma. [18]